SR
LXRX icon

Syntax Research’s Lexicon Pharmaceuticals LXRX Stock Holding History

Syntax Research’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$341 Hold
142
– – ﹤0.01% 178
2026
Q1 		$222 Hold
142
– – ﹤0.01% 173
2025
Q4 		$164 Hold
142
– – ﹤0.01% 172
2025
Q3 		$192 Hold
142
– – ﹤0.01% 172
2025
Q2 		$135 Hold
142
– – ﹤0.01% 170
2025
Q1 		$66 Hold
142
– – ﹤0.01% 175
2024
Q4 		$105 Hold
142
– – ﹤0.01% 183
2024
Q3 		$223 Hold
142
– – ﹤0.01% 190
2024
Q2 		$239 Hold
142
– – ﹤0.01% 174
2024
Q1 		$341 Hold
142
– – ﹤0.01% 168
2023
Q4 		$218 Hold
142
– – ﹤0.01% 175
2023
Q3 		$155 Buy
+142
New +$249 ﹤0.01% 178

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Syntax Research's LXRX Position: Q2 2026 in Review

Syntax Research held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 142 shares worth $341. The position accounts for ﹤0.01% of the portfolio, ranked #178.

Syntax Research first reported a position in LXRX in Q3 2023 and has held it in 12 quarters since. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Syntax Research held 142 shares of Lexicon Pharmaceuticals worth $341 as of Q2 2026.
  • Syntax Research left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Syntax Research's portfolio in Q2 2026, its #178 holding.
  • Syntax Research first reported a position in Lexicon Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Syntax Research's 13F filing for Q2 2026, filed 31 Jul 2026.